Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
ACAD Stock Chart & Stats
$25.99
-$0.09(-0.52%)
At close: 4:00 PM EST
$25.99
-$0.09(-0.52%)
Day’s Range― - ―
52-Week Range$13.40 - $28.35
Previous CloseN/A
Volume443.16K
Average Volume (3M)1.25M
Market Cap
$4.40B
Enterprise Value$4.19B
Total Cash (Recent Filing)$847.02M
Total Debt (Recent Filing)$54.81M
Price to Earnings (P/E)16.7
Beta1.04
Next Earnings
Mar 02, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.42
Shares Outstanding169,181,820
10 Day Avg. Volume1,231,729
30 Day Avg. Volume1,254,982
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)4.15
Price to Sales (P/S)3.17
P/FCF Ratio19.34
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue4.01
Enterprise Value/Gross Profit4.36
Enterprise Value/Ebitda35.75
Forecast
1Y Price Target
$31.15Price Target Upside19.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)0.75
Revenue Forecast (FY)$1.21B
Bulls Say, Bears Say
Bulls Say
ACP-204 Clinical ReadoutA Phase 2 ACP-204 topline readout expected in mid-2026 could act as a major pipeline catalyst if the clinician-rated psychosis endpoint demonstrates meaningful benefit.
Daybue Access And TolerabilityApproval of Daybue STIX and a new powder formulation could improve tolerability, reduce gastrointestinal issues and enable patients who could not swallow large liquid volumes to start or resume therapy, potentially boosting treatment persistence.
Nuplazid Demand And Commercial ExpansionExpanded direct-to-consumer awareness combined with plans to increase the customer-facing sales team by about 30% starting in 1Q26 aims to drive more referrals and new prescriptions, supporting near-term commercial growth.
Bears Say
Community Prescriber FamiliarityLower familiarity among community physicians with rare diseases can lead to slower prescribing patterns for Rett-related therapies, limiting uptake outside specialized centers.
Regulatory Risk In Ex-US MarketsA negative CHMP opinion in 1Q26 would pose downside risk to ex‑US sales forecasts and could delay or reduce international revenue opportunities.
ACADIA Pharmaceuticals News
ACAD FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $13.40 and its highest was $28.35 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
ACADIA Pharmaceuticals’s market cap is $4.40B.
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is Mar 02, 2026 which is in 42 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on Nov 05, 2025. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.173 by $0.247.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is 0.14.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 169,181,820 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of $0.42 in its last earnings report, beating expectations of $0.173. Following the earnings report the stock price went down -3.045%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Currently, no hedge funds are holding shares in ACAD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ACADIA Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$31.15 (19.85% Upside)
$31.15 (19.85% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 64.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $670.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.34%
12-Months-Change
Fundamentals
Return on Equity
34.95%
Trailing 12-Months
Asset Growth
36.23%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
ACAD Company Deck
ACAD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with robust revenue growth and strategic investments in DAYBUE and NUPLAZID, alongside pipeline advancements. However, challenges persist with DAYBUE's market penetration and increased R&D expenses.View all ACAD earnings summariesACAD Stock 12 Month Forecast
Average Price Target
$31.15
▲(19.85% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
PTC Therapeutics
―
Krystal Biotech
―
MoonLake Immunotherapeutics
―
Arcellx Inc
―
Ownership Overview
Currently, No data available
---